3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Failure
1
Hepatitis C
1
Hepatitis B
1
Hepatic Insufficiency
1
HIV Infections
1
Carcinoma, Hepatocellular
1
Interventions
Capecitabine
9
Bevacizumab
8
tislelizumab
7
Oxaliplatin
7
Drug Therapy
7
pembrolizumab
6
Surgical Procedures, Operative
6
Standard of Care
6
Cisplatin
6
Radiotherapy
5
Laparoscopy
5
Fluorouracil
5
Docetaxel
5
Carboplatin
5
toripalimab
4
Radiosurgery
4
Leucovorin
4
Exercise
4
Epirubicin
4
Cyclophosphamide
4
pertuzumab
3
durvalumab
3
dalpiciclib
3
atezolizumab
3
anlotinib
3
Saline Solution
3
Rituximab
3
Radiation
3
Prednisone
3
Population Groups
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Raltegravir Potassium
×
1 year
×
Clear all
NCT01022476
2026-04-06
LIVERAL
ANRS, Emerging Infectious Diseases
Phase 1/2
Completed
14 enrolled